Valvular heart disease in patients taking pergolide

Mayo Clinic Proceedings

Volumn 77, Issue 12, 2002, Pages 1280-1286

  Pritchett, Allison M ^a   Morrison, John F ^a   Edwards, William D ^a   Schaff, Hartzell V ^a   Connolly, Heidi M ^a   Espinosa, Raul E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; ERGOTAMINE; FENFLURAMINE; METHYSERGIDE; PERGOLIDE;

AGED; ARTICLE; CARCINOID SYNDROME; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART VALVE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MORPHOLOGY; PHYSICAL EXAMINATION; SURGICAL TECHNIQUE; TREATMENT PLANNING; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

EID: 0036894736     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.12.1280     Document Type: Article

References (27)

1. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J. 1974;88:640-655.
2. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med. 1992;117:50-52.
3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [published correction appears in N Engl J Med. 1997;337:1783]. N Engl J Med. 1997; 337:581-588.
4. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
5. Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry. 1999;66:79-81.
6. Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol. 1995;18:277-279.
7. Mondal BK, Suri S. Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract. 2000;54:403.
8. Hauck AJ, Freeman DP, Ackermann DM, Danielson GK, Edwards WD. Surgical pathology of the tricuspid valve: A study of 363 cases spanning 25 years. Mayo Clin Proc. 1988;63:851-863.
9. Pfeiffer RF, Ebadi M. Pharmacologic management of Parkinson's disease. In: Cohen AM, Weiner WJ, eds. The Comprehensive Management of Parkinson's Disease. New York, NY: Demos Publications; 1994:23-24.
10. Chesson AL Jr, Wise M, Davila D, et al, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder: An American Academy of Sleep Medicine Report. Sleep. 1999;22:961-968.
11. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966;274:359-368.
12. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci. 1967;254:1-12.
13. Taal BG, Spierings EL, Hilvering C. Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine. Thorax. 1983;38:396-398.
14. Ward CD, Thompson J, Humby MD. Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment. J Neurol Neurosurg Psychiatry. 1987;50:1706-1707.
15. Bowler JV, Ormerod IE, Legg NJ. Retroperitoneal fibrosis and bromocriptine [letter]. Lancet. 1986;2:466.
16. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease [letter]. Lancet. 1981;1: 44-45.
17. Hauck AJ, Edwards WD, Danielson GK, Mullany CJ, Bresnahan DR. Mitral and aortic valve disease associated with ergotamine therapy for migraine: Report of two cases and review of literature. Arch Pathol Lab Med. 1990;114:62-64.
18. Misch KA. Development of heart valve lesions during methysergide therapy. BMJ, 1974;2:365-366.
19. Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: A study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002; 77:139-147.
20. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75-81.
21. Pellikka PT, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188-1196.
22. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol. 1999;24:745-792.
23. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): Receptor agonist and antagonists. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:281-284.
24. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology. 1994;33:275-317.
25. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102:2836-2841.
26. Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J. 1996;9:1013-1019.
27. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc. 1999;74:1191-1197.